CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CZNF274::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CRFX3::JAK2FusionDiagnosticSupportsPositiveB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeReshmi et al., 2017
CBRCA2K3326*PredictiveSupportsSensitivity/ResponseGlioblastomaTemozolomide,OlaparibValiakhmetova et al., 2020
CBRAFN486_P490delPredictiveSupportsSensitivity/ResponsePancreatic CancerTrametinibAguirre et al., 2018
CNRF1::BRAFFusionPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaTrametinibIsaacson et al., 2019
CCDKN2Ac.151-1G>CPredisposingSupportsPredispositionMelanomaPetronzelli et al., 2001
DBCR::ABL1Fusion AND ABL1 T315IPredictiveDoes Not SupportResistanceAcute Lymphoblastic LeukemiaAxitinib,PonatinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceAcute Lymphoblastic LeukemiaImatinib,Dasatinib,NilotinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 T315IPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaPonatinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Dasatinib,ImatinibPemovska et al., 2015
CRCSD1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaImatinibPerwein et al., 2016
CMET::ATXN7L1FusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibZhu et al., 2018
CMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseHistiocytic And Dendritic Cell CancerCrizotinibFrampton et al., 2015
DMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseCancerCapmatinibFrampton et al., 2015
DERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerAfatinibLeto et al., 2015
CFGFR1AmplificationPredictiveSupportsSensitivity/ResponseAdenosquamous Lung CarcinomaPazopanibMalchers et al., 2014
CBCR::ABL1Fusion AND ABL1 H396RPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CFGFR2P253RPredictiveSupportsSensitivity/ResponseHead And Neck Squamous Cell CarcinomaPazopanibLiao et al., 2013
DBCR::ABL1FusionPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinib,Bafetinib,DasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceCancerImatinib,DasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceCancerImatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 T315APredictiveDoes Not SupportResistanceCancerBafetinib,NilotinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 F317VPredictiveDoes Not SupportResistanceCancerNilotinib,Bafetinib,ImatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 T315APredictiveSupportsResistanceCancerDasatinib,ImatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 F317VPredictiveSupportsResistanceCancerDasatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 H396PPredictiveDoes Not SupportResistanceCancerBafetinib,NilotinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 H396PPredictiveSupportsResistanceCancerImatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 Y253FPredictiveSupportsResistanceCancerImatinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceCancerImatinib,BafetinibDeguchi et al., 2008
DBCR::ABL1Fusion AND ABL1 M244VPredictiveSupportsResistanceCancerBafetinib,ImatinibDeguchi et al., 2008
CJAK1OVEREXPRESSIONPredictiveSupportsSensitivity/ResponseSarcomaRuxolitinibNewton et al., 2018
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceCancerBafetinib,ImatinibDeguchi et al., 2008
DEML4::ALKFusion AND ABCB1 OverexpressionPredictiveSupportsResistanceLung AdenocarcinomaCrizotinib,CeritinibKatayama et al., 2016
DLYNOVEREXPRESSIONPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBafetinib,DasatinibDeguchi et al., 2008
BPRPS1A190TPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaLi et al., 2015
CVHLL188V (c.562C>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseLui et al., 2002
CVHLL178Q (c.533T>A)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
CVHLR161Q (c.482G>A)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
CVHL106insR (c.316insGCC)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
CVHLN78S (c.233A>G)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
CVHLC77_N78insL (c.230_231insTCT)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
CVHLC162W (c.486C>G)PredisposingN/AVon Hippel-Lindau DiseaseLui et al., 2002
DPRPS1A190TPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaLometrexol,MercaptopurineLi et al., 2015
DPRPS1D139GPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaThioguanine,MercaptopurineLi et al., 2015
DPRPS1C77SPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1I72VPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaThioguanine,MercaptopurineLi et al., 2015
DPRPS1V53APredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMercaptopurine,ThioguanineLi et al., 2015
DPRPS1L191FPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMethotrexate,Asparaginase,DaunorubicinLi et al., 2015
DPRPS1S103TPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaMethotrexate,Cytarabine,Asparaginase,DaunorubicinLi et al., 2015
DPRPS1S103NPredictiveDoes Not SupportResistanceB-lymphoblastic Leukemia/lymphomaCytarabine,Asparaginase,Methotrexate,DaunorubicinLi et al., 2015
Page 56 of 96
PreviousNext